登革热临床试验核心结局测量集:国际德尔菲共识研究(DEN-CORE)
登革热临床试验的结局和测量工具异质性高,限制可比性和证据合成。本研究遵循COMET和COS-STAD指南,分两阶段:第一阶段通过系统文献综述、患者访谈、管理组和指导委员会审核、两轮改良德尔菲调查及结构化在线共识会议,制定住院和早期登革热的核心结局集(COS);第二阶段通过靶向测量工具综述和混合国际共识研讨会最终确定核心结局测量集(COMS)。住院登革热COMS包括7个结局,早期登革热COS在此基础上增加4个结局;重症监护试验推荐使用现有ICU专用COS;为9个临床医生报告的结局制定了统一定义。
要点
- 住院登革热临床试验的共识COMS包括7个结局,早期登革热COS包括这7个结局加另外4个。
- 重症监护登革热试验推荐使用现有的ICU专用核心结局集(COS)。
- 为9个临床医生报告的结局制定了统一定义。
- 共识通过两轮改良德尔菲调查和结构化在线共识会议形成,并遵循COMET和COS-STAD指南。
- DEN-CORE COMS旨在协调登革热试验的结局选择和测量,提高可比性并支持政策和临床决策。
适用人群与场景
- 住院登革热患者和早期登革热患者的临床试验。
- 重症监护试验人群参照现有ICU专用核心结局集。
研究设计与关键结果
- 研究为国际德尔菲共识研究,遵循COMET和COS-STAD指南,分两阶段进行。
- 第一阶段通过系统文献综述、患者定性访谈、管理组和指导委员会审核、两轮改良德尔菲调查及结构化在线共识会议制定COS。
- 第二阶段通过靶向结局测量工具综述和混合国际共识研讨会最终确定COMS。
- 住院登革热COMS包括7个结局;早期登革热COS包括这7个结局加另外4个结局。
- 重症监护试验推荐使用现有ICU专用COS。
- 为9个临床医生报告的结局制定了统一定义。
证据类型、等级与局限
- 证据类型:国际德尔菲共识研究。
- 遵循COMET和COS-STAD指南。
- 局限:原文未报告局限性。
对床旁实践的改变
- 登革热临床试验应使用DEN-CORE COMS统一结局选择和测量,以提高试验间可比性并支持证据合成。
- 重症监护登革热试验应采用现有ICU专用核心结局集,而非另行制定登革热专用重症结局集。
- 临床医生报告的9个结局应使用DEN-CORE制定的统一定义。
指南或共识出处
- DEN-CORE共识研究(Lancet Infect Dis)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Dengue, caused by any one of four distinct virus serotypes, is the most rapidly spreading mosquito-borne viral disease worldwide. It is a primary arboviral infection with increasing global incidence, driven by climate change, urbanisation, and the expanding range of Aedes mosquito vectors. Despite growing research interest, outcome and measurement instrument heterogeneity in dengue clinical trials remains high, limiting comparability and evidence synthesis. This project aimed to develop a globally relevant Core Outcome Measurement Set (COMS) for use in dengue clinical trials through international consensus. This consensus study followed core outcome measures in effectiveness trials and Core Outcome Set-Standards for Development (COS-STAD) guidelines and was conducted in two phases. Phase 1 focused on developing a Core Outcome Set (COS) through four steps: (1) a systematic literature review; (2) qualitative interviews with people with lived experience of dengue; (3) review by the management group and steering committee; (4) a two-round modified Delphi survey and structured online consensus meetings to finalise the COS for hospitalised and early stages of dengue disease. Input from critical care experts informed recommendations for the intensive care unit (ICU) and high dependency unit COS. Phase 2 consisted of a further two steps: (1) targeted review of outcome measurement instruments; and (2) a hybrid international consensus workshop to finalise the COMS. The agreed COMS for hospitalised dengue included seven outcomes; the early stage dengue COS included these outcomes plus four more. For critical care trials, use of existing ICU-specific COS was recommended. Unified definitions were developed for nine clinician-reported outcomes. The DEN-CORE COMS provides a consensus-based framework for harmonising outcome selection and measurement in dengue trials, improving comparability and supporting policy and clinical decision making.
参考来源
- Yacoub S, Demidova A, Chan XHS, et al. Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE). Lancet Infect Dis. 2025. PMID: 41072450. doi:10.1016/S1473-3099(25)00500-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。